Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Yuhan Corporation is a prominent entity in the pharmaceutical industry, dedicated to the research, development, and distribution of a wide range of medical products and services. Headquartered in South Korea, Yuhan Corporation is involved in manufacturing prescription drugs, over-the-counter medications, and active pharmaceutical ingredients, supporting both domestic and international markets. In addition to pharmaceuticals, the company also explores biotechnological innovations and manufacturing partnerships to diversify its product offerings. Yuhan Corporation plays a critical role in improving public health by investing in cutting-edge research and fostering collaborations with global pharmaceutical leaders to bring innovative therapies to market. Its comprehensive portfolio addresses various medical needs, influencing sectors from general healthcare to specialized treatments. With a strong emphasis on corporate responsibility and sustainability, Yuhan Corporation prioritizes ethical business practices and environmental stewardship, contributing to its stature as a leading name in the pharmaceutical landscape.
₩70,100.00
₩400.00 (-0.57%)
Live · 05:29 PM
Operating margin is thin at 4.77%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 5.7%, steady but not accelerating.
At 25x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -₩38.51B. The business is consuming cash, not generating it.
25.0x earnings. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩2.22T
▲ +5.7% YoY
Net Income (TTM)
₩198.68B
▲ +235.9% YoY
Op. Margin
4.81%
▲ +2.1pp YoY
ROIC
3.37%
▲ +1.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-₩1.94B
▲ +51.4% YoY
Op. Cash Flow (TTM)
₩190.76B
▲ +459.0% YoY
Net Debt
-₩38.41B
Net Cash Position
Cash & Equiv.
₩378.08B
3Y CAGR: +7.2%
Continue Research
At a P/E of 25.0, A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Yuhan scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.7%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Yuhan scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 4.8% operating margin and a 3.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Yuhan pays a regular dividend of about KRW 501.72 per share per year (typically in quarterly installments), a yield of roughly 0.7% at the current price. That is a payout ratio of about 18.9% of earnings, so the dividend is amply covered by earnings. Yuhan has grown the dividend at roughly 10.7% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 000100.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh 000100.XKRX's valuation and scores 50/100 on quality (mixed). It also yields about 0.7%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.